125 related articles for article (PubMed ID: 20815108)
21. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
[TBL] [Abstract][Full Text] [Related]
22. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir gel studied.
AIDS Patient Care STDS; 2002 Aug; 16(8):401-2. PubMed ID: 12227991
[No Abstract] [Full Text] [Related]
24. [Conclusions. Tenofovir].
Mallolas J
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
[No Abstract] [Full Text] [Related]
25. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Pulido F; Fiorante S
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
[TBL] [Abstract][Full Text] [Related]
26. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
27. The North Carolina contribution to the CAPRISA 004 study: the Global Health Initiative in action.
Cates W; Kashuba AD
N C Med J; 2010; 71(5):490-1. PubMed ID: 21473558
[No Abstract] [Full Text] [Related]
28. Tenofovir disoproxil fumarate.
Antoniou T
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
[No Abstract] [Full Text] [Related]
29. GlaxoSmithKline halts AIDS study.
Clarke B
Lancet Infect Dis; 2003 Sep; 3(9):530. PubMed ID: 12968626
[No Abstract] [Full Text] [Related]
30. Women testing tenofovir for HIV prevention.
AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747428
[No Abstract] [Full Text] [Related]
31. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Polk C; Chan-Tack KM; Kopack AM; Amoroso A
AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
[No Abstract] [Full Text] [Related]
32. Leveraging rapid implementation of an HIV treatment policy to reduce confounding in observational analysis of antiretroviral outcomes.
Vinikoor MJ; Moyo C
Trop Med Int Health; 2014 May; 19(5):499-500. PubMed ID: 24646005
[No Abstract] [Full Text] [Related]
33. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
[TBL] [Abstract][Full Text] [Related]
34. What they say about: nucleotide drugs.
Posit Aware; 2000; 11(1):55. PubMed ID: 11366352
[TBL] [Abstract][Full Text] [Related]
35. Anti-HIV agents. Trying times for tenofovir and abacavir.
TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
[No Abstract] [Full Text] [Related]
36. First of a kind in HIV treatment.
FDA Consum; 2006; 40(6):34. PubMed ID: 17333565
[TBL] [Abstract][Full Text] [Related]
37. Tenofovir-related nephrotoxicity: an ongoing clinical challenge.
Foisy MM; Hughes C; Hills-Nieminen C; Singh AE; Joffe AM
Am J Health Syst Pharm; 2013 Aug; 70(15):1272-4. PubMed ID: 23867482
[No Abstract] [Full Text] [Related]
38. Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
Quinn KJ; Emerson CR; Dinsmore WW; Donnelly CM
Int J STD AIDS; 2010 Feb; 21(2):150-1. PubMed ID: 20090006
[No Abstract] [Full Text] [Related]
39. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
[No Abstract] [Full Text] [Related]
40. Investigating new antiretroviral combinations.
Carr A
J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
